Search by Categories
- Insights
- Rare Disease
- Oncology
- Cell and Gene Therapy
- Medical Devices
- Consulting
- News & Analysis
-
Therapeutic Areas
Our expertise in the industry
The innovation in the oncology drug pipeline has resulted in a record number of FDA and EU approvals in recent years, as investigators and sponsors seek new and targeted treatments for individuals...
Noxxon continues enrolment in a glioblastoma therapy trial Noxxon Pharma continues subject enrolment in the GLORIA clinical trial of NOX-A12 in brain cancer (glioblastoma) patients. The move co...
Although COVID-19 continued to dominate headlines in 2021, pharmaceutical companies did not cease developing new treatments this year. The US Food and Drug Administration maintained a rapid rate o...
Edwards secures FDA approval for Sapien 3 with Alterra Prestent for Transcatheter Pulmonic Valve Replacement Edwards Lifesciences declared to receive approval from the U.S. Food and Drug Admini...
T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is a relatively new immunological checkpoint that has been studied as a potential immunotherapeutic target. TIGIT is a transmembrane glycopro...
Progress is driven by innovation. When it comes to developing novel medications and therapeutic biological products, the FDA's Center for Drug Evaluation and Research (CDER) assists the pharmaceut...
The treatment options for Non-Small Cell Lung Cancer (NSCLC) have been flooded in recent years due to improved methods of molecular profiling and better diagnostic tools. The new molecular b...
FDA Validates Use of Amgen’s KRAS Inhibitor in Lung Cancer In a pathbreaking move, Amgen has gone ahead to emerge as a trailblazer in the undruggable lung cancer space with the approval o...
Promega Biotech Ibérica Gains Recognition for COVID-19 Response in Spain Promega Biotech Ibérica has been heralded as the business leader in Spain for its COVID-19 response. The company’s innov...
Clover Biopharmaceuticals Raises $230 Million Clover Biopharmaceuticals announced the completion of an oversubscribed $230 million Series C financing, summing total capital raised by the ...
With the advent of new-age healthcare industry trends that are evident as of now, there...
Although COVID-19 continued to dominate headlines in 2021, pharmaceutical companies did...
The Biosimilars market is growing at a breakneck pace. The biosimilar market provides a...
Chimeric antigen receptor T-cell (CAR T) therapies are shown to have transformative pot...
There has been limited progress in the approval of novel agents in MDS. It has been a l...
Hear from our subject-matter experts and in-house KOL’s on Pharma and Healthcare market trends.
